Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Creative Medical Technology Holdings Q3 2026 Results: Net Loss of $2.67M, Loss Widens

Creative Medical Technology Holdings reported a net loss of $5.59 million for the nine months ended September 30, 2026, driven by increased research and development and SG&A expenses. The company remains in a pre-revenue stage for the current period, though it successfully raised approximately $4.06 million through warrant exercises and stock sales to support its regenerative therapy pipeline.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Gross profit0.00.0
Profit before tax-2.7-1.2
Net income-2.7-1.2
EPS (diluted, $ a share)$-0.40$-0.48

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CELZ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Creative Medical Technology Holdings, Inc.: key numbers

Share price
$0.5201Close, Nov 16
Market cap
$3.95M
Shares outstanding
7.6MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Creative Medical Technology Holdings, Inc.

All →
4:07 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Creative Medical Technology Holdings Nasdaq/NYSE Compliance Notice

Creative Medical Technology Holdings received a deficiency notice from Nasdaq on November 10, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has until May 10, 2027, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days. The notice has no immediate impact on the listing of the company's common stock (CELZ).

Counterparty
The Nasdaq Stock Market
Term
180 days
5:01 PM ET 8-K
M&A Deal

Creative Medical Technology Holdings M&A Deal with BioDefense, Inc.

Creative Medical Technology Holdings acquired 4,000,000 shares of BioDefense, Inc. from Creative Acquisition Corp. for $200,000 in cash and 1,000,000 shares of its own common stock. Following the transaction, the company owns 80% of BioDefense, Inc., making it a majority-owned subsidiary.

Counterparty
BioDefense, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.